55706-91-7

Usage

Uses

Used in Pharmaceutical Industry:
(17β)-Spiro[androsta-1,4-diene-17,2'-oxiran]-3-one is used as an intermediate in the preparation of a urinary metabolite of the human doping agent Methandienone (Methandrostenolone, M226000). This application is significant for the development of tests and methods to detect the use of performance-enhancing drugs in sports and other竞技 (competitive) environments.

Upstream product

• 571-35-7 3β-hydroxy-13α-methylandrost-5-en-17-one 
• 18462-31-2 3β-hydroxy-13α-methylandrost-5-en-17-one acetate 
• 853-23-6 prasterone acetate 

Relevant academic research and scientific papers

Synthesis of 17β-hydroxymethyl-17α-methyl-18-norandrosta-1,4,13-trien-3-one: A long-term metandienone metabolite

The goal of this work was a good-yielding chemical synthesis of a metandienone metabolite which is of interest in doping analysis. 20βOH-NorMD (IUPAC: 17β-hydroxymethyl-17α-methyl-18-norandrosta-1,4,13-triene-3-one) has been identified as a long-term urinary metabolite which can be detected and attributed to metandienone up to almost 3?weeks after exposure. The chemical synthesis of its epimer 20αOH-NorMD has been described before, as was an enzymatic synthesis of 20βOH-NorMD, but no chemical synthesis was published.